Risk factors in the acquisition of extended-spectrum β-lactamase Klebsiella pneumoniae: A case-control study in a district teaching hospital in Taiwan

Journal of Hospital Infection

Volumn 53, Issue 1, 2003, Pages 39-45

  Lin, Ming Feng ^a   Huang, M L ^a   Lai, S H ^a  

^a Hsin Chu General Hospital   (Taiwan)

Author keywords

Ceftazidime; ESBLs; K. pneumoniae; Risk factors

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAMASE; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CLAVULANIC ACID; PENICILLIN DERIVATIVE; QUINOLONE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BALLOON CATHETER; CASE CONTROL STUDY; CENTRAL VENOUS CATHETER; CHILD; CONTROLLED STUDY; ENDOTRACHEAL TUBE; ENTEROBACTERIACEAE; ENZYME SYNTHESIS; FEMALE; HUMAN; KLEBSIELLA PNEUMONIAE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NASOGASTRIC TUBE; NONHUMAN; PREVALENCE; PSEUDOMONAS AERUGINOSA; RISK ASSESSMENT; RISK FACTOR; STATISTICAL ANALYSIS; TAIWAN; TEACHING HOSPITAL; TRACHEOSTOMY;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CATHETERIZATION; CEFTAZIDIME; CEPHALOSPORIN RESISTANCE; FEMALE; HOSPITALIZATION; HOSPITALS, DISTRICT; HOSPITALS, TEACHING; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS; TAIWAN; TRACHEOSTOMY;

EID: 0142252609     PISSN: 01956701     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhin.2002.1331     Document Type: Article

References (35)

1. National nosocomial infection surveillance (NNIS)system report, data summary from January 1992- April 2000, issued June 2000. Am J Infect Control 2000;28: 429-448.
2. Medeiros, AA (1997). Evolution and dissemination of β-lactamases accelerated by generations of β-lactam antibiotics. Clin Infect Dis, 24 S19-S45.
3. Knothe, H, Shah, P, & Krcmery, V et al. (1983). Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection, 11 315-317.
4. De Champs, C, Rouby, D, & Guelon, D et al. (1991). A case-control study of an outbreak of infections caused by Klebsiella pneumoniae strains producing CTX-1 (TEM-3) beta-lactamase. J Hosp Infect, 18 5-13.
5. Meyer, KS, Urban, D, & Eagan, JA et al. (1993). Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med, 119 353-358.
6. Lucet, JC, Chevret, S, & Decre, D et al. (1996). Outbreak of multiply resistant Enterobacteriaceae in an intensive care unit: epidemiology and risk factors for acquisition. Clin Infect Dis, 22 430-436.
7. Pena, C, Pujol, M, & Ardanuy, C et al. (1998). Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum β-lactamases. Antimicrob Agents Chemother, 42 53-58.
8. Jarlier, V, Nicolas, MH, & Fournier, G et al. (1988). Extended broad-spectrum β-lactamases conferring transferable resistance to newer β-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis, 10 67-78.
9. Chanal, C, Sirot, D, & Romaszko, JP et al. (1996). Survey of prevalence of extended-spectrum β-lactamases among Enterobacteriaceae. J Antimicrob Chemother, 38 127-132.
10. Philippon, A, Labia, R, & Jacoby, G (1989). Extended-spectrum β-lactamases. Antimicrob Agents Chemother, 33 1131-1136.
11. Jacoby, GA, & Medeiros, AA (1991). More extended-spectrum β-lactamases. Antimicrob Agents Chemother, 35 1697-1704.
12. Bush, K, Jacoby, GA, & Medeiros, AA (1995). A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother, 39 1211-1233.
13. Philippon, A, Arlet, G, & Lagrange, PH (1994). Origin and impact of plasmid-mediated extended-spectrum β-lactamases. Eur Clin Microbiol Infect Dis, 13 S17-S29.
14. Katsanis, GP, Spargo, J, & Ferraro, MJ et al. (1994). Detection of Klebsiella pneumoniae and Escherichia coli strains producing extended-spectrum β-lactamases. J Clin Microbiol, 32 691-696.
15. Jacoby, GA, & Han, P (1996). Detection of extended-spectrum β-lactamases in clinical isolates of Klebsiella pneumonias and Escherichia coli. J Clin Microbiol, 34 908-911.
16. Wong-Beringer, A (2001). Therapeutic challenges associated with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Pharmacotherapy, 21 583-592.
17. National Committee for Clinical Laboratory Standards, Performance standards for antimicrobial susceptibility testing: eleventh informational supplement, 2001, 21, 40-44
18. Sanders, CC, Barry, AL, & Washington, JA et al. (1996). Detection of extended-spectrum-β-lactamase-producing members of the family Enterobacteriaceae with the Vitek ESBL test. J Clin Microbiol, 34 2997-3001.
19. Vercauteren, E, Descheemaeker, P, & Ieven, M et al. (1997). Comparison of screening methods for detection of extended-spectrum β-lactamases and their prevalence among blood isolates of Escherichia coli and Klebsiella spp. In a Belgian teaching hospital. J Clin Microbiol, 35 2191-2197.
20. Garner, JS, Jarvis, WR, & Emori, TG et al. (1988). CDC definitions for nosocomial infections, 1988. Am J Infect Control, 16 128-140.
21. Brun-Buisson, C, Legrand, P, & Rauss, A et al. (1989). Intestinal decontamination for control of nosocomial multi-resistant Gram-negative bacilli: study of an outbreak in an intensive care unit. Ann Intern Med, 110 873-881.
22. Schiappa, DA, Hayden, MK, & Matushek, MG et al.(1996). Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: a case-control and molecular epidemiologic investigation. J Infect Dis, 174 529-536.
23. Rebuck, JA, Olsen, KM, & Fey, PD et al. (2000). Characterization of an outbreak due to extended-spectrum β-lactamase-producing Klebsiella pneumoniae in a pediatric intensive care unit transplant population. Clin Infect Dis, 31 1368-1372.
24. Menashe, G, Borer, A, & Yagupsky, P et al. (2001). Clinical significance and impact on mortality of extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates in nosocomial bacteraemia. Scand J infect Dis, 33 188-193.
25. Livermore, DM, & Yuan, M (1996). Antibiotic resistance and production of extended-spectrum beta-lactamases amongst Klebsiella spp. from intensive care units in Europe. J Antimicrob Chemother, 38 409-424.
26. Pangon, B, Bizet, C, & Bure, A et al. (1989). In vivo selection of a cephamycin-resistance, porin-deficient mutant of Klebsiella pneumoniae producing a TEM-3 β-lactamase. J Infect Dis, 159 1005-1006.
27. Peterson, DL (2000). Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs). Clin Microbiol Infect, 6 460-463.
28. Burwen, DR, Banerjee, SN, Gaynes, RP, & The National Nosocomial Infection Surveillance System, (1994). Ceftazidime resistance among selective nosocomial gram-negative bacilli in the United States. J Infect Dis, 170 1622-1625.
29. Itokazu, GS, Quinn, JP, & Bell-Dixon, C et al (1996). Antimicrobial resistance rates among aerobic Gram-negative bacilli recovered from patients in intensive care unit: evaluation of a national postmarketing surveillance program. Clin Infect Dis, 23 779-784.
30. Jan, IS, Hsueh, PR, & Teng, LJ (1998). Antimicrobial susceptibility testing for Klebsiella pneumoniae isolates resistant to extended-spectrum beta-lactam antibiotics. J Formos Med Assoc, 97 661-666.
31. Liu, PY, Tung, JC, & Ke, SC et al. (1998). Molecular epidemiology of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae isolates in a district hospital in Taiwan. J Clin Microbiol, 36 2759-2762.
32. Yan, JJ, Wu, SM, & Tsai, SH et al. (2000). Prevalence of SHV-12 among clinical isolates of Klebsiella pneumoniae producing extended-spectrum beta-lactamases and identification of a novel AmpC enzyme (CMY-8) in Southern Taiwan. Antimicrob Agents Chemother, 44 1438-1442.
33. Pena, C, Pujol, M, & Ricart, A et al. (1997). Risk factors for faecal carriage of Klebsiella pneumoniae producing extended spectrum beta-lactamase (ESBL-KP) in the intensive care unit. J Hosp Infect, 35 9-16.
34. Lautenbach, E, Patel, JB, & Bilker, WB et al. (2001). Extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumonia: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis, 32 1162-1171.
35. Piroth, L, Aube, H, & Doise, JM et al. (1998). Spread of extended-spectrum β-lactamases-producing Klebsiella pneumoniae: are β-lactamase inhibitors of therapeutic value?. Clin Infect Dis, 27 76-80.